Literature DB >> 6116285

Diazepam-cimetidine drug interaction: a clinically significant effect.

R L Ruffalo, J F Thompson, J L Segal.   

Abstract

Cimetidine has been shown to inhibit the liver microsomal metabolism of the benzodiazepines diazepam and chlordiazepoxide, resulting in an increase in half-life and decrease in the clearance of these two drugs. Patients receiving the combination of diazepam and cimetidine have been noted to be more sedated than when given an equal dose of diazepam alone. Many benzodiazepines undergo N-dealkylation and hydroxylation via the cytochrome P450 oxidase system. Cimetidine is thought to bind to cytochrome P450 oxidase and to interfere with many drugs using this path way. Oxazepam and lorazepam are two benzodiazepines not oxidatively metabolized by cytochrome P450, but are glucuronidated by glucuronyl transferase and are, therefore, not subject to metabolic inhibition by cimetidine. Thus, when clinically indicated, oxazepam and lorazepam may be the benzodiazepines of choice to use in combination with cimetidine to eliminate the clinically significant drug interaction seen with diazepam and chlordiazepoxide.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6116285     DOI: 10.1097/00007611-198109000-00016

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  4 in total

Review 1.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

Review 2.  Clinical significance of the cytochrome P450 2C19 genetic polymorphism.

Authors:  Zeruesenay Desta; Xiaojiong Zhao; Jae-Gook Shin; David A Flockhart
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 3.  Pharmacokinetic interactions of cimetidine 1987.

Authors:  A Somogyi; M Muirhead
Journal:  Clin Pharmacokinet       Date:  1987-05       Impact factor: 6.447

4.  Synergistic action of phage phiIPLA-RODI and lytic protein CHAPSH3b: a combination strategy to target Staphylococcus aureus biofilms.

Authors:  Ana Catarina Duarte; Lucía Fernández; Vincent De Maesschalck; Diana Gutiérrez; Ana Belén Campelo; Yves Briers; Rob Lavigne; Ana Rodríguez; Pilar García
Journal:  NPJ Biofilms Microbiomes       Date:  2021-04-22       Impact factor: 7.290

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.